Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds - 2First Houthi launch toward Israel since war began triggers alerts across the Negev
- 3Extraordinary Guinness World Records That Will Astound You
- 4The Best Cell phone Brands for Tech Lovers
- 5Fundamental Home Machines for Improved Solace in Summer
- Dominating Capable Mastercard Utilization: Key Contemplations
- Vagus nerve stimulation shows promise as a way to counter Alzheimer’s disease- and age-related memory loss
- Home Remodel Administrations: Change Your Residing Space
- Manageable Living: Eco-Accommodating Decisions for Regular day to day existence
- Spotify Wrapped and Apple Music Replay are here: Top songs, albums and artists of 2025
- Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago
- Innovative Versatility: Examples of overcoming adversity from Entrepreneurs
- What to know about voluntary chocolate recall
- Aurora chaser catches a fox basking in the glow of Finland's legendary 'fox fires' (photos)
